Europe Bioinformatics Market Report 2022 to 2030

Europe Bioinformatics Market Analysis

$ 3999

The Europe Bioinformatics market is projected to grow from $2.92 Bn in 2022 to $8.95 Bn by 2030, registering a CAGR of 15.04% during the forecast period of 2022 - 2030. The main factors driving the growth would be technological advancement, growing research in the field of bioinformatics, increasing need for bioinformatics for personalized medicine, and the treatment of various chronic diseases. The market is segmented by technology and by application. Some of the major players include BioWisdom, Biomax Informatics, Qiagen, Thermo Fisher Scientific, and Agilent Technologies.

ID: IN10EUHS001 CATEGORY: Healthcare Services GEOGRAPHY: Europe AUTHOR: Neha Davda

Buy Now

Europe Bioinformatics Market Executive Summary

The Europe Bioinformatics market is projected to grow from $2.92 Bn in 2022 to $8.95 Bn by 2030, registering a CAGR of 15.04% during the forecast period of 2022 – 2030. In recent years, the Europe region's healthcare spending has increased as a result of the aging of the population, the rising prevalence of chronic diseases, and the rising demand for high-quality healthcare services. According to data from the World Health Organization (WHO), healthcare spending as a percentage of GDP varies significantly across European countries. In several countries, including the UK, Germany, France, Italy, and Spain, healthcare spending is quite high as a percentage of GDP.

Bioinformatics is the study of biology with information technology. In bioinformatics, various approaches are used, such as data management, data mining, data warehousing, and data generation. Statistical techniques and data processing algorithms are provided by bioinformatics software and tools as integrated solutions for applications including next-generation sequencing, modeling of genomic and proteomic structure, and three-dimensional drug discovery. In the global bioinformatics market, Europe holds the second largest share.

europe bioinformatics market analysis

Market Dynamics

Market Growth Drivers

The Europe bioinformatics market is expected to be driven by factors such as technological advancement, growing research in the field of bioinformatics, and an increasing need for bioinformatics for personalized medicine and the treatment of various chronic diseases. By using genome-focused pharmacology to treat chronic diseases, bioinformatics has the potential to revolutionize oncology and advance the idea of precision medicine.

Market Restraints

High cost of R&D and challenges in clinical bioinformatics analysis such as effective evaluation of analytical software tools, acceleration of the overall process using hybrid parallel computing (HPC) parallelization and acceleration technology, advancement of automation techniques, alternatives for data storage, etc. restricts the growth of bioinformatics in Europe.

Competitive Landscape

Key Players

BioWisdom
Biomax Informatics
Qiagen
Thermo Fisher Scientific
Agilent Technologies

Notable Recent Deals

September 2022: Thermo Fisher Scientific joins the Pennsylvania Biotechnology Center (PABC) as a founding sponsor of both the PABC location in Pennsylvania and the B+Labs incubator in Philadelphia, where up-and-coming life sciences companies can accelerate their path to commercialization.

Healthcare Policies and Regulatory Landscape

Several government organizations, including the European Medicines Agency (EMA), the European Commission (EC), and national competent authorities like the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the French National Agency for Medicines and Health Products Safety (ANSM), shape the healthcare policies and regulatory landscape for the Europe bioinformatics market. These organizations are in charge of policing the creation, endorsement, and promotion of bioinformatics goods and services in Europe. A comprehensive data privacy rule called the General Data Protection Regulation (GDPR) has an impact on how sensitive personal health data is used and stored in the European bioinformatics market.

The European bioinformatics industry is also shaped by intellectual property rules, such as patents, trademarks, and copyrights, which defend businesses' rights to use and market their bioinformatics goods and services.

Reimbursement Scenario

The European bioinformatics market's reimbursement scenario is complicated and varies widely by nation. Government funding for particular bioinformatics goods and services may exist in some nations, although private insurance and/or out-of-pocket expenses may be the primary means of payment in other nations. The type of good or service, along with the unique healthcare system in each nation, might have an impact on the amount of compensation offered. The technology's cost-effectiveness and ability to improve patient outcomes will both be taken into consideration when deciding whether to provide payment.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Bioinformatics Market Segmentation

By Technology (Revenue, USD Billion):

Knowledge Management Tools
Bioinformatics Platforms
Bioinformatics Services

By Application (Revenue, USD Billion):

Metabolomics
Molecular phylogenetics
Transcriptomics
Chemoinformatic & drug design
Genomics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.